Roche struck a strategic agreement with Nvidia to construct a high‑capacity AI compute facility intended to accelerate drug discovery and diagnostics development. The deal will supply Roche with large‑scale GPU infrastructure and software collaboration to train generative and predictive models for target identification, molecule design and biomarker discovery. Industry reporting noted the move follows similar investments by peers such as Eli Lilly and underscores major pharmas’ push to integrate large compute and AI workflows into R&D pipelines to compress discovery timelines and improve translational yields.